Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study
Year: 2020
Type: erratum
Abstract: The authors of the above mentioned article would like to highlight the following corrections, based upon recent changes to the FDA label and guidance on the use of belamaf
Source: Ophthalmology and Therapy
Authors: Asim V. Farooq, Simona Degli Esposti, Rakesh Popat, Praneetha Thulasi, Sagar Lonial, Ajay K. Nooka, Andrzej Jakubowiak, Douglas Sborov, Brian E. Zaugg, Ashraf Z. Badros, Bennie H. Jeng, Natalie S. Callander, Joanna Opalinska, January Baron, Trisha Piontek, Julie Byrne, Ira Gupta, Kathryn Colby
Institutions: University of Chicago Medical Center, Moorfields Eye Hospital NHS Foundation Trust, NIHR Moorfields Biomedical Research Centre, University College London, University College London Hospitals NHS Foundation Trust, Emory University, Emory Eye Center, Winship Cancer Institute, Huntsman Cancer Institute, University of Utah, University of Maryland, Baltimore, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, GlaxoSmithKline (United States)
Language: English
Topic: Drug-Induced Ocular Toxicity
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $5,100
OpenAlex ID: W4232610523